Anthony Patron

“Pleasure to meet over the phone, and hope you're doing well, John. One on procedure volumes, just a broader question, and one on capital allocation. You know, all three, you know, segments could be used as a proxy for procedure volumes.”

“Maybe Chris, Jim, one on IVT, and then I'll have one on plasma. Nice to see IVT coming back to growth here, organic growth, 2.5%. Gave some details there in your prepared remarks, Chris, but maybe a little bit more color on the dynamics of share shift.”

“I was muted hopping across calls here, but congrats on the strong start to the year. Maybe just on TrueView into the TPT ruling and just launch, how that's going to sort of work out from a contracting perspective.”

“Maybe on the Penn Needle contract, obviously a competitive loss there, but just wondering the length of the contract in terms of the loss there and when maybe it comes up for renewal.”

“Maybe going back to tariffs, just wondering how the $55 million splits between Romainco and Spinco or the sale here, and how are you going to just sort of navigate mitigation between the two entities as we move into the second half of the year and all the quick follow-up?”